BioDrugs

, Volume 20, Issue 1, pp 67–70 | Cite as

Spotlight on Infliximab in Crohn Disease and Rheumatoid Arthritis

Adis Spotlight

Abstract

Infliximab (Remicade®) is a chimeric monoclonal antibody against tumor necrosis factor (TNF)-α that has shown efficacy in Crohn disease and rheumatoid arthritis with a disease-modifying activity and rapid onset of action. It is administered intravenously, generally in a schedule with initial infusions at 0, 2, and 6 weeks, followed by administration once every 8 weeks.

Infliximab is effective in the treatment of patients with moderately to severely active Crohn disease with an inadequate response to other treatment options or those with fistulizing disease. In combination with methotrexate, infliximab reduced signs and symptoms and delayed disease progression in patients with active, methotrexate-refractory rheumatoid arthritis and in those with early disease. The drug was generally well tolerated. Recrudescence of tuberculosis infection and worsening of heart failure and demyelinating disease are among some of the concerns with anti-TNFα therapy, requiring cautious use of these agents in high-risk patients.

Current data suggest that infliximab may be cost effective, especially when long-term clinical outcomes and burden of the diseases are taken into account. More robust, prospective pharmacoeconomic studies are required to better ascertain the cost effectiveness of infliximab.

Direct head-to-head comparative trials of infliximab with other biological agents are not yet available and would be helpful in determining with greater certainty the place of infliximab in the management of these diseases. Nonetheless, infliximab, like other biological agents, is a valuable treatment option in patients with moderately to severely active Crohn disease (including fistulizing disease) or rheumatoid arthritis (including early disease).

Keywords

Rheumatoid Arthritis Infliximab Crohn Disease Single Infusion Infliximab Therapy 

Notes

Acknowledgments

The full text article in Drugs 2005; 65 (15): 2179–208 was reviewed by H. Asakura, International Medical Information Center, Shinjukuku, Tokyo, Japan; F. Breedveld, Department of Rheumatology, Leiden University Hospital, Leiden, The Netherlands; T. Ikawa, Osaka Rehabilitation Hospital, Osaka, Japan; P.J. Rutgeerts, Gastroenterology Section, Faculty of Medicine, University of Leuven, Leuven, Belgium; S. Schreiber, Department of General Internal Medicine and Institute for Clinical Molecular Biology, Christian-Albrechts-University, Schittenhelmstrasse, Kiel, Germany; W.S. Selby, Department of Medicine, University of Sydney, Sydney, Australia; G. Valesini, Division of Rheumatology, La Sapienza University, Rome, Italy.

References

  1. 1.
    Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30(16): 1443–53PubMedCrossRefGoogle Scholar
  2. 2.
    van den Brande JMH, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol Suppl 2005 Mar; 74: 26–30PubMedGoogle Scholar
  3. 3.
    Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. Biodrugs 2002; 16(2): 111–48PubMedCrossRefGoogle Scholar
  4. 4.
    Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 2001 Apr; 15(4): 463–73PubMedCrossRefGoogle Scholar
  5. 5.
    Centocor Inc. Product information (US): Remicade for IV injection (infliximab 100mg vial) [online]. Available from URL: http://www.remicade.com [Accessed 2005 May 10]
  6. 6.
    Centocor B.V. Product information (EU): Remicade 100mg powder for concentrate for solution for infusion (infliximab lOOmg vial) [online]. Available from URL: http://www.emea.eu.int/ [Accessed 2005 May 10]
  7. 7.
    Boyle A, Tawadros R, Zhu Y, et al. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn’s disease patients. Gastroenterology 2002 Apr; 122Suppl. 1: A614–5. Plus poster presented at Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association; 2002 May 19–23; San Francisco (CA)Google Scholar
  8. 8.
    Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000 Apr; 27(4): 841–50PubMedGoogle Scholar
  9. 9.
    Rutgeerts P, D’Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999 Oct; 117(4): 761–9PubMedCrossRefGoogle Scholar
  10. 10.
    Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 Apr; 50(4): 1051–65PubMedCrossRefGoogle Scholar
  11. 11.
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factora monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552–63PubMedCrossRefGoogle Scholar
  12. 12.
    Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 2003 Apr; 98: 833–8PubMedCrossRefGoogle Scholar
  13. 13.
    Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 Nov 30; 343(22): 1594–602PubMedCrossRefGoogle Scholar
  14. 14.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002 May 4; 359: 1541–9PubMedCrossRefGoogle Scholar
  15. 15.
    St. Clair EW, van der Heijde DMFM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomised controlled trial. Arthritis Rheum 2004 Nov; 50(11): 3432–43CrossRefGoogle Scholar
  16. 16.
    Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 1997; 337(15): 1029–35PubMedCrossRefGoogle Scholar
  17. 17.
    Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol 2002 Apr; 29: 667–77PubMedGoogle Scholar
  18. 18.
    D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999 May; 116(5): 1029–34PubMedCrossRefGoogle Scholar
  19. 19.
    Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 Oct; 98(10): 2232–8PubMedCrossRefGoogle Scholar
  20. 20.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004 Feb 26; 350(9): 876–85PubMedCrossRefGoogle Scholar
  21. 21.
    Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004 May; 36(5): 342–7PubMedCrossRefGoogle Scholar
  22. 22.
    Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003 May; 36(5): 632–6PubMedCrossRefGoogle Scholar
  23. 23.
    deRidder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in the Netherlands. J Pediatr Gastroenterol Nutr 2004 Jul; 39(1): 46–52CrossRefGoogle Scholar
  24. 24.
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999 Dec 4; 354(9194): 1932–9PubMedCrossRefGoogle Scholar
  25. 25.
    Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005 Jan; 52(1): 27–35PubMedCrossRefGoogle Scholar
  26. 26.
    Taylor PC, Steuer A, Gruber J, et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 2004 Apr; 50(4): 1107–16PubMedCrossRefGoogle Scholar
  27. 27.
    Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor alpha antagonists. Drug Saf 2004; 27(5): 307–24PubMedCrossRefGoogle Scholar
  28. 28.
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 2001 Oct 21; 345(15): 1098–104PubMedCrossRefGoogle Scholar
  29. 29.
    Geborek P, Bladstrom A, Turesson C, et al. TNF blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with increased risk of lymphomas. Ann Rheum Dis 2005; 64(5): 699–703PubMedCrossRefGoogle Scholar
  30. 30.
    Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 May 20; 138(10): 807–11PubMedGoogle Scholar
  31. 31.
    Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44(12): 2862–9PubMedCrossRefGoogle Scholar
  32. 32.
    Bodger K. Economic implications of biological therapies for Crohn’s Disease: review of infliximab. Pharmacoeconomics 2005; 23(9): 875–88PubMedCrossRefGoogle Scholar
  33. 33.
    Wong JB, Loftus Jr EV, Sandborn WJ, et al. Estimating the cost-effectiveness of infliximab for Crohn’s disease [abstract no. G0451]. Gastroenterology 1999 Apr; 116(4 Pt 2): 104–5Google Scholar
  34. 34.
    Wong JB, Loftus EV, Sandborn WJ, et al. A cost-effectiveness analysis of maintenance infliximab for chronic active Crohn’ s disease in Canada [abstract no. G398]. Gut 2004; 53Suppl. 6: 232Google Scholar
  35. 35.
    Colombel JF, Rutgeerts P, Yan S, et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn’s disease patients [abstract no. W1344]. Gastroenterology 2002 Apr; 122Suppl. 1: A613Google Scholar
  36. 36.
    Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005 Apr; 128(4): 862–9PubMedCrossRefGoogle Scholar
  37. 37.
    Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004; 22(2): 107–32PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations